ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: LB19 • ACR Convergence 2025

    Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial

    Jonathan Graf1, Amy Archer2, Sergiy Kovalenko3, Katarzyna Kolossa4, John Serpa5, Tamta Kobakhidze6, Daniela Cepoi7, Andrea Everding8, Costantino Pitzalis9, Catherine Aversa2, Martin Dahl2, May Hafez2, Paul Lizzul2, Priya Raina2, Bruce Randazzo2, Yangsu Ren2, Khalil Saikali2, Cailin Sibley10, Gerd Burmester11, Jacques-eric GOTTENBERG12, Iain McInnes13, Eduardo Mysler14, Lee Simon15, Josef Smolen16, Jeffrey Sparks17, Ronald van Vollenhoven18, Michael Weinblatt19 and Paul Emery20, 1UCSF, San Francisco, California, 2AnaptysBio Inc, San Diego, California, 3Arensia Exploratory Medicine, Kyiv, Ukraine, 4MICS Centrum Medyczne, Bydgoszcz, Poland, 5Allied Biomedical Research Institute, Miami, Florida, 6Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, 7Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, 8MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, 9QMUL, Bromley Kent, United Kingdom, 10AnaptysBio Inc, San Diego, 11Charité - Universitétsmedizin Berlin, Berlin, Germany, 12Hautepierre Hospital, STRASBOURG, France, 13University of Glasgow, Glasgow, United Kingdom, 14OMI, Buenos Aires, Argentina, 15SDG LLC, West Newton, Massachusetts, 16Medical University of Vienna, Vienna, Austria, 17Brigham and Women's Hospital, Boston, Massachusetts, 18Amsterdam UMC, Amsterdam, Netherlands, 19Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, 20University of Leeds, Leeds, United Kingdom

    Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
  • Abstract Number: 2564 • ACR Convergence 2025

    An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments

    Mie Fusama1, Hideko Nakahara2, Megumi Okada3, Kayoko Sakagami4, Ikuyo Noguchi5, Harumi Matsumura6, Hiroaki Ito4, Kosaku Oda5, Yoshitaka Shinto3, Kenshi Higami6, Satomi Higami6 and Tetsuya Tomita7, 1Kansai University of International Studies, Miki, Japan, 2Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan, 3Shinto Orthopaedics and Rheumatology Clinic, Osaka, Japan, 4Infusion Clinic, Osaka, Japan, 5Oda Orthopedic Surgery Rheumatology Clinic, Nishinomiya, Japan, 6Higami Clinic of Rheumatology and Diabetology, Kashihara, Japan, 7Morinomiya University of Medical Sciences, Osaka, Japan

    Background/Purpose: RA patients frequently encounter challenges in effectively communicating their symptoms to medical professionals. Recently, the “Okomarigoto Sheet” (OS), an illustration-based patient-reported outcome measure for…
  • Abstract Number: 2144 • ACR Convergence 2025

    The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis

    Jessica Bloom1, Kaci Pickett-Nairne2, Lori Silveira1, Cristina Burroughs3, Katrina Bargender4, Amy Bolton4, Christine Yeung4, Jennifer Gordon5, Peter Merkel6 and Karen James7, 1University of Colorado, Aurora, CO, 2University of Colorado, Denver, 3University of South Florida, Tampa, FL, 4Vasculitis Patient-Powered Research Network, Philadelphia, PA, 5Vasculitis Foundation, Kansas City, MO, 6University of Pennsylvania, Philadelphia, PA, 7University of Utah, Salt Lake City, UT

    Background/Purpose: ANCA-associated vasculitis (AAV) is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether this impact varies based on…
  • Abstract Number: 1558 • ACR Convergence 2025

    Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study

    Thomas Guedens1, Elvira Lesmana2, Adam Edwinson3, Margaret Breen-Lyles1, Anukul Karn4, Madhusudan Grover1 and Ashima Makol3, 1Mayo Clinic, Rochester, Rochester, MN, 2Mayo Clinic, Rochester, USA, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Trinity Health Livonia, Farmington Hills, MI

    Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem auto-immune disease characterized by peripheral vasculopathy and widespread fibrosis of the skin and internal organs. Up to…
  • Abstract Number: 1266 • ACR Convergence 2025

    Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?

    Jennifer Barton1, Joshua Baker2, gabriela Schmajuk3, Madhavi Valiveti4, Alexandra Bennett5, Benjamin Morasco6, Allison O'Neill7 and Meike Niederhausen8, 1VA Portland Health Care System/OHSU, Portland, OR, 2University of Pennsylvania, Philadelphia, PA, 3University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, 4VAMC Wilmington, Wilmington, DE, 5Center to Improve Veteran Involvement in Care (CIVIC) and VA Portland Health Care System, Portland, OR, 6Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, 7Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, 8Oregon Health & Science University/VA Portland Health Care System, Portland, OR

    Background/Purpose: Shared decision making (SDM) is outlined as the first overarching principle of the treat to target guidelines for rheumatoid arthritis (RA). The quality of…
  • Abstract Number: 0564 • ACR Convergence 2025

    Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor

    Alice Gottlieb1, Joseph F Merola2, Philip J. Mease3, Christopher Ritchlin4, Jose U. Scher5, Kimberly Parnell Lafferty6, Daphne Chan7, Soumya Chakravarty8, Wayne Langholff9, Yanli Wang9, Olivia Choi, MD, PhD, FAAD7, Yevgeniy Krol10 and Alexis Ogdie11, 1Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, 2Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 3Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 4University of Rochester Medical Center, Canandaigua, NY, 5New York University School of Medicine, New York, NY, 6Johnson & Johnson, Dermatology, Horsham, PA, 7Johnson & Johnson, Horsham, PA, USA, Horsham, PA, 8Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, 9Johnson & Johnson, Biostatistics, Spring House, PA, 10Johnson & Johnson, Horsham, PA, 11University of Pennsylvania School of Medicine, Philadelphia, PA

    Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated efficacy in significantly improving psoriatic arthritis (PsA) signs and symptoms in participants (pts) with active…
  • Abstract Number: 0379 • ACR Convergence 2025

    Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study

    Rosa Maria Morlà Novell1, Enrique González-Dávila2, Beatriz Frade Sosa3, Maria López-Lasanta4, Noemí Busquets Pérez5, Marta Valls Roc6, Meritxell Sallés Lizarzáburu7, Georgina Salvador Alarcón8, Virginia Ruiz-Esquide9, Lola Tobalina Mastre10, José Gomez-Puerta11 and Raimon Sanmartí9, 1Hospital Clínic de Barcelona, Barcelona, Spain, 2Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain, 3Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 4Hospital Universitari Vall d´Hebron, Barcelona, Spain, 5Hospital de Granollers, Granollers, Spain, 6Hospital Universitari Dr Trueta, Girona, Sudan, 7Xarxa Sanitària Althaia Manresa, Manresa, Spain, 8Hospital Universitari Mùtua Terrassa, Terrassa, Spain, 9Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, 10IDIBAPS. Hospital Clinic de Barcelona, Barcelona, 11Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain

    Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…
  • Abstract Number: 0153 • ACR Convergence 2025

    Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER

    Isabel Castrejón Fernández1, Lucia Otero2, Antonio Mera-Valera3, Alicia Garcia4, Silvia Gomez-Sabater5, Raquel Martín-Domenech6, Jose Alvaro-Gracia7, Juan Camilo Sarmiento-Monroy8, Beatriz Ventosa2 and Fernando Sánchez-Alonso9, 1Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3H. Clínico Universitario de Santiago, Santiago de Compostela, 4Rheumatologist, La Laguna, Spain, 5Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, 6H. Universitario de Elda, Elda, Spain, 7Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, 8Hospital Clínic Barcelona, Barcelona, Spain, 9Sociedad Española de Reumatología, Madrid, Spain

    Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of…
  • Abstract Number: 2553 • ACR Convergence 2025

    Impact of Polypharmacy on Treatment Adherence and Its Effect on The Quality of Life in Patients with Rheumatic Diseases

    Egla Samantha Sanchez-Peralta1, Margarita Isabel Alarcon-Jarquin2, Vanessa L. Lopez-Flores2, Dionicio A. Galarza-Delgado3 and Diana E. Flores-Alvarado1, 1Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, 2Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

    Background/Purpose: Treatment adherence is fundamental for adequate control of rheumatic diseases. Nevertheless, due to the chronic nature of these conditions, polypharmacy can impact treatment adherence,…
  • Abstract Number: 2098 • ACR Convergence 2025

    Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial

    Natalie Keller1, Bryant England2, Katherine Wysham3, Mercedes Quinones4, Marianna Olave5, Sarah Wetzel6, Hannah Brubeck7, Rachel Gillcrist6, Criswell Lavery8, Bibiana Ateh9, Bridget Kramer2, Kimberly Hayes6, Rui Xiao8, Kaitian Jin8, Alexis Ogdie8, Daniel K. White10, Tuhina Neogi11, Carla Scanzello12 and Joshua Baker8, 1University of Oklahoma, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4Howard University Hospital and Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, 5Brown University, Philadelphia, PA, 6Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 7VA Puget Sound Health Care System, Seattle, WA, 8University of Pennsylvania, Philadelphia, PA, 9Washington VA Medical Center, Washington, District of Columbia, 10University of Delaware, Newark, DE, 11Boston University School of Medicine, Boston, MA, 12University of Pennsylvania, Philadelphia

    Background/Purpose: Intra-articular (IA) corticosteroid injections are commonly utilized for pain management in knee osteoarthritis (KOA). However, clinical characteristics associated with a greater benefit from corticosteroid…
  • Abstract Number: 1505 • ACR Convergence 2025

    Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada

    Romy Kallas1, Naiva Manuela Piatchou Donfack1, Deanna Jannat-Khah1, Cynthia Aranow2, Cristina Arriens3, Jill Buyon4, Megan Clowse5, Maria Dall'Era6, Richard Furie7, Ellen Ginzler8, Jennifer Grossman9, Kenneth Kalunian10, Diane Kamen11, Kichul Ko12, William McCune13, Brad Rovin14, Francisco Sanchez-Guerrero15, Saira Sheikh16, Kyriakos Kirou1 and Timothy Niewold17, 1Hospital for Special Surgery, New York, NY, 2Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4NYU Grossman School of Medicine, New York, NY, 5Duke University, Chapel Hill, NC, 6Division of Rheumatology, University of California, San Francisco, CA, 7Division of Rheumatology, Northwell Health, Great Neck, NY, 8SUNY Downstate Health Sciences University, New York, NY, 9UCLA, Sherman Oaks, CA, 10UC San Diego, La Jolla, CA, 11Medical University of South Carolina, Johns Island, SC, 12The University of Chicago, Chicago, IL, 13U Michigan, Ann Arbor, MI, 14The Ohio State University, Columbus, OH, 15University Health Network/Sinai Health system, Toronto, ON, Canada, 16University of North Carolina at Chapel Hill, Chapel Hill, NC, 17Hospital for Special Surgery, New York, New York

    Background/Purpose: Understanding the discordance between patient- and physician-reported disease assessment scores is essential for incorporating patient-reported outcomes into disease activity measures and identifying gaps between…
  • Abstract Number: 1262 • ACR Convergence 2025

    Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study

    Cristina Arriens1, Fredonna Carthen2, Alexandre Cammarata-Mouchtouris1, Judith James1, Joan Merrill3 and Motolani Ogunsanya4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma, OK, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Lupus has profound impact on physical, social, and emotional well-being. Health-related quality of life (HRQOL) measures are increasingly incorporated into lupus research and the…
  • Abstract Number: 0816 • ACR Convergence 2025

    Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs

    Andreas Kerschbaumer1, Marlene Steiner2, William H. Robinson3, Josef Smolen4 and Daniel Aletaha5, 1Stanford University / Medical University of Vienna, Stanford, CA, 2Medical University of Vienna, Vienna, Wien, Austria, 3Stanford University, Palo Alto, CA, 4Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 5Medical University Vienna, Wien, Austria

    Background/Purpose: Joint swelling and tenderness are clinical hallmarks of rheumatoid arthritis (RA) and central to disease assessment. Regardless of treatment type, stringent remission based on…
  • Abstract Number: 0378 • ACR Convergence 2025

    Identifying Patterns of Telemedicine Readiness and Digital Health Literacy in Rheumatoid Arthritis Patients: A Latent Class Analysis

    Preeti Dhanasekaran1, Bryant Lim2, Qai Ven Yap2, Hafizah Ahmad3, Siew Hwa Chong3, Ginny Goh3, Manjari Lahiri4, Amelia Santosa4, Gim Gee Teng3, Peter Cheung4, Siriwan Lim1 and Margaret Ma4, 1National University of Singapore, Singapore, Singapore, 2National University of Singapore, Singapore, 3National University Hospital, Singapore, 4National University Hospital, Singapore, Singapore

    Background/Purpose: The COVID-19 pandemic accelerated telemedicine adoption, yet readiness and digital literacy vary widely across patient populations. Understanding these differences is crucial to designing equitable…
  • Abstract Number: 2539 • ACR Convergence 2025

    Patient-reported outcomes in patients with polymyalgia rheumatica under rheumatology care: baseline data from the ENRICH-PMR cohort

    Sebastian E Sattui1, Amy Mudano2, Yujie Su2, Sandeep Sodhi3, Fenglong Xie4, Iris Navarro-Millan5, Robyn Domsic6 and Jeffrey Curtis7, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, 3Illumination Health, Hoover, AL, 4The University of Alabama at Birmingham, Birmingham, AL, 5Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, 6University of Pittsburgh, Pittsburgh, PA, 7University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Worse health-related quality of life has been reported in individuals with polymyalgia rheumatica (PMR), yet the factors contributing to this burden – including the…
  • 1
  • 2
  • 3
  • …
  • 50
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology